

# ARCUS OVERVIEW

NYSE: RCUS

ARCUS  
BIOSCIENCES

Global, clinical-stage biopharmaceutical company at the forefront of designing novel combination therapies for cancer

## HIGHLY PRODUCTIVE DRUG DISCOVERY

Small Molecules & Antibodies Designed to Be Combined



**Targets:** CD73, HIF-2 $\alpha$ , A2 $\alpha$ /2 $\beta$ , AXL



**Targets:** TIGIT, PD-1, CD39

Goal of **1-2**  
new molecules advancing  
into clinic each year



**Accelerated**  
P 1/2 signal-seeking & platform studies

## DIVERSE PIPELINE & KEY DATA FOR 2025+

**7**



Different molecules in clinic

**1<sup>st</sup>** Pivotal Readout



for Fc-silent anti-TIGIT dom Phase 3 Study with potential approval and revenue generation anticipated in 24-36 months

**3+** HIF-2 $\alpha$  Cas Events



- Cas monotherapy PFS data
- Cas + cabo combination safety data
- Planned initiation of Phase 3 cas + cabo study

**\$10B+**



Addressable market opportunity in the U.S. based on expected drug treatable patient population

## TOP-TIER PARTNERS FOR STRATEGIC & CLINICAL COLLABORATIONS



Funding:

**~\$1.7B**

- Holds ~30% equity stake in Arcus
- 50/50 Cost-sharing for certain optioned programs
- Co-development / co-commercialization in the U.S.



## STRONG FINANCIAL POSITION & CASH RUNWAY WITH FUNDING THROUGH MULTIPLE PHASE 3 READOUTS



**~\$1B** cash, cash equivalents & marketable securities as of 3/31/2025

## HQ & RESEARCH CAMPUSES IN BAY AREA



**~600** employees

Learn more at  
[investors.arcusbio.com](https://investors.arcusbio.com)

Except as stated otherwise, this summary is provided as of 5/6/2025. For a more complete description of our business and risks and uncertainties that may affect forward-looking statements made in this summary, including the statement regarding funding through multiple Phase 3 readouts, please refer to our full corporate presentation and latest Form 10-K and Form 10-Q, which can be found at [investors.arcusbio.com](https://investors.arcusbio.com). The runway estimate is based on cash, cash equivalents, marketable securities, and available facilities.

cabo: cabozantinib, cas: casdatifan, dom: domvanalimab, PFS: progression-free survival